Actively Recruiting
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
Led by Angitia Incorporated Limited · Updated on 2026-01-23
30
Participants Needed
1
Research Sites
42 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
CONDITIONS
Official Title
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy males or females aged 18 to 65 years
- 25-hydroxyvitamin D level of at least 30 ng/mL and agree to take calcium and vitamin D supplements during the study
- Meet the criteria for Japanese, Chinese, or Caucasian ethnicity
You will not qualify if you...
- Participated in another clinical trial within the past 6 months
- Had any bone fracture within the past 6 months
- History of myocardial infarction or stroke within the past 12 months
- Diagnosed with malignancy within the past 5 years
- Currently have hypercalcemia or hypocalcemia
- Pregnant or breastfeeding, or planning to become pregnant during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Los Angeles EPCU
Glendale, California, United States, 91206
Actively Recruiting
Research Team
K
Kimberly Brown
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here